Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.
Sector: Services-Medical Laboratories
Industry: Biotechnology
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 282.60M shares outstanding
USCaris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally.
The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms.
Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.
Brian J. Brille
Executive Vice Chairman & Executive Vice President
David Dean Halbert
Chairman, Chief Executive Officer & Founder
David Dean Halbert, D. Sc. (h.c.)
Nominated for Election to a Term Expiring at the 2027 Annual Meeting; Founder, Chairman and Chief Executive Officer
David Fredrickson
EVP, Oncology Business Unit of AstraZeneca PLC; Executive Vice-President, Oncology Business Unit
Employees
2K+
Country
US
Sector
Healthcare
Website
carislifesciences.com
Loading congressional disclosures…
based on 282.60M shares outstanding
US30d Avg
5.31M
60d Avg
5.09M
90d Avg
5.00M
